1. Home
  2. FLYW vs NAMS Comparison

FLYW vs NAMS Comparison

Compare FLYW & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flywire Corporation Voting

FLYW

Flywire Corporation Voting

HOLD

Current Price

$17.13

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$22.58

Market Cap

2.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLYW
NAMS
Founded
2009
2019
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.5B
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
FLYW
NAMS
Price
$17.13
$22.58
Analyst Decision
Buy
Strong Buy
Analyst Count
14
8
Target Price
$16.21
$46.75
AVG Volume (30 Days)
1.2M
1.4M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
450.00
32.81
EPS
0.03
N/A
Revenue
$623,025,000.00
$22,503,000.00
Revenue This Year
$19.68
$17.96
Revenue Next Year
$15.25
$540.65
P/E Ratio
$577.67
N/A
Revenue Growth
26.59
N/A
52 Week Low
$10.55
$21.02
52 Week High
$19.73
$42.21

Technical Indicators

Market Signals
Indicator
FLYW
NAMS
Relative Strength Index (RSI) 39.85 35.55
Support Level $17.09 N/A
Resistance Level $19.02 $37.29
Average True Range (ATR) 0.62 1.41
MACD -0.16 -0.07
Stochastic Oscillator 15.61 25.44

Price Performance

Historical Comparison
FLYW
NAMS

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: